Download Files:
GSK-872
$42 – $750
Products Details
Product Description
– GSK-872 is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM. GSK-872 decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury[1][2][3].
Web ID
– HY-101872
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C19H17N3O2S2
Citations
– Acta Pharmacol Sin. 2021 Aug 10.|Am J Cancer Res. 2021 May 15;11(5):2062-2080.|Biochem Biophys Res Commun. 2020 Jun 11;526(4):1028-1035.|Biochem Biophys Res Commun. 2023 Sep 17, 673, 51-58.|Biomed Pharmacother. 2020 Jun;126:110102.|bioRxiv. 2023 Apr 25.|BMC Gastroenterol. 2022 Mar 26;22(1):137.|Cancer Lett. 2023 May 5;216208.|Cell Death Differ. 2022 Jan 22.|Cell Death Dis. 2021 Mar 3;12(3):230.|Cell Death Dis. 2020 Feb 19;11(2):134.|Cell Death Discov. 2022 Feb 2;8(1):44.|Cell Death Discov. 2022 Feb 26;8(1):88.|Cell Mol Life Sci. 2022 Jun 4;79(6):340.|Cell Res. 2023 Aug 14.|Cell Res. 2023 Mar;33(3):201-214.|Chin J of Oncol Prev and Treat. 2018, 10(2): 105-109.|Clin Cancer Res. 2022 Nov 30;CCR-22-1591.|CNS Neurosci Ther. 2023 Aug 8.|EMBO Rep. 2023 Oct 17:e56865.|Eur J Immunol. 2020 Jun;50(6):795-808.|Exp Neurol. 2020 Sep;331:113374.|FASEB J. 2022 Dec;36(12):e22625.|Front Cell Infect Microbiol. 2022 Feb 4;12:825824.|Front Physiol. 2019 Jan 15;9:1922.|Immunol Cell Biol. 2021 Jan;99(1):34-48.|Int Immunopharmacol. 2022 Sep 24;112:109262.|Int J Mol Sci. 2022 Sep 5;23(17):10170.|Invest New Drugs. 2020 Feb;38(1):50-59|iScience. 21 September 2021.|J Immunol. 2018 Apr 15;200(8):2826-2834.|J Med Chem. 2019 May 9;62(9):4772-4778.|J Stroke Cerebrovasc Dis. 2021 Nov 24;31(1):106213.|J Virol. 2022 Jun 13;e0016722.|Korean J Physiol Pharmacol. 2023 May 1;27(3):231-240.|Life Sci. 2021 Sep 16;285:119963.|Mol Immunol. 2022 Dec 9;153:160-169.|Molecules. 2020 Mar 9;25(5):1225.|Nat Cell Biol. 2022 Apr;24(4):471-482.|Nature. 2020 Apr;580(7803):386-390. |OncoTargets and Therapy Dovepress. 2020 May 18;15:1093-1101.|PLoS One. 2022 Oct 12;17(10):e0274116.|Research Square Preprint. 2023 Oct 3.|Research Square Print. 2022 May.|Research Square Print. January 4th, 2023.|Signal Transduct Target Ther. 2020 Oct 9;5(1):235.|SSRN. 26 Oct 2022.|Stroke. 2018 Oct;49(10):2473-2482.|Transl Stroke Res. 2021 Dec;12(6):991-1017.|Research Square Print. September 23rd, 2022.
References
– [1]Mandal P, et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell. 2014 Nov 20;56(4):481-95.|[2]Arora D, et al. Deltamethrin induced RIPK3-mediated caspase-independent non-apoptotic cell death in rat primary hepatocytes. Biochem Biophys Res Commun. 2016 Oct 14;479(2):217-223.|[3]Chen T, et al. Inhibiting of RIPK3 attenuates early brain injury following subarachnoid hemorrhage: Possibly through alleviating necroptosis. Biomed Pharmacother. 2018;107:563-570.
CAS Number
– 1346546-69-7
Molecular Weight
– 383.49
Compound Purity
– 99.91
SMILES
– O=S(C1=CC=C2N=CC=C(C2=C1)NC3=CC=C4SC=NC4=C3)(C(C)C)=O
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– RIP kinase
Isoform
– RIPK3
Pathway
– Apoptosis
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
